B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design by Reddy, V et al.
Background
B cells have been targeted in the treatment of systemic 
lupus erythematosus (SLE) and rheumatoid arthritis (RA) 
owing to the central role they play in the pathogenesis of 
these disorders. Th ese cells play a critical role in host 
defence through their maturation into antibody-secreting 
plasma cells, secretion of proinﬂ ammatory cytokines, 
antigen presentation and co-stimulatory support for T cells. 
However, dysfunctional recognition of self-antigens as 
nonself-antigens results in autoantibody production, 
sustained by plasma cells derived from the B-cell lineage 
that survive for prolonged periods in the lymphoid 
tissues. B cells also participate in inﬂ ammatory reactions 
through antibody-independent mechanisms by acting as 
antigen-presenting cells and co-stimulation of T cells and 
other inﬂ ammatory cell types, although as yet there are 
no validated biomarkers that distinguish pathogenic from 
protective B-cell subsets. Reagents that speciﬁ cally target 
pathogenic B-cell subsets are therefore not likely to be 
available in the near future. Th is reality provides the 
rationale for targeting B cells in patients with SLE, RA 
and other autoimmune diseases [1-5].
B-cell-targeted immunotherapy was initially developed 
for the treatment of B-cell-related malignancies, which 
are associated with poor prognosis despite aggressive 
cyto toxic therapies. Of the many surface-expressed anti-
gens on B cells studied as possible targets, CD20  – a 
trans membrane phosphoprotein expressed in normal B 
cells as well as 90% of lymphomas  – is not shed or 
modulated, making it an attractive target. In 1994, Reﬀ  
and colleagues reported a major (95%) and sustained (up 
to 90  days) B-cell depletion using a murine mAb (2B8) 
that targeted CD20 on B cells in nonhuman primates [6]. 
In 1997, a landmark study reported on both the safety 
and eﬃ  cacy of rituximab, a chimeric (mouse–human) 
mAb directed against CD20, for the treatment of 
relapsed, refractory low-grade or follicular lymphoma 
[7]. In November 1997, rituximab was licensed for this 
indication. Rituximab is now a part of the standard thera-
peutic regimen in the management of B-cell malignancies 
and remains among the most successful therapeutic 
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mAbs. Interestingly, the response rate is variable amongst 
individuals with the same histological type of lymphoma 
as well as the overall response rate between diﬀ erent 
histological types [8]. Th is suggests that B-cell depletion 
is not uniform across patients or indeed diseases for 
reasons yet to be fully understood, but Fcγ receptor 
function appears important with enhanced Fcγ receptor 
IIb expression being associated with reduced rituximab 
eﬃ  cacy in lymphoma [9]. Intriguingly, polymorphisms of 
this receptor are associated with SLE, although their 
precise role in the disease and potential for targeted 
therapeutic intervention is not understood.
In 1999, Professor Edwards’ group at University College 
London treated a small number of patients with refrac-
tory RA using rituximab, having been encouraged by the 
safety and eﬃ  cacy proﬁ le of induced transient depletion 
of B cells in haematological malignancies. Th is study and 
subsequent studies of rituximab in RA, including a large 
phase II randomised controlled trial, indicated that the 
treatment was potentially safe and eﬀ ective [10-13]. Th e 
regimen in these studies utilised two doses (1,000 mg) of 
rituximab given 2  weeks apart, with premedication in-
clud ing a single 100  mg intravenous dose of methyl-
prednisolone and 10 mg chlorphenamine. In the original 
study, patients also received a course of high-dose 
prednisolone (60 mg for up to 3 weeks and then tapering 
over the next 3 to 4 weeks or maintaining at 5 mg a day). 
Responding patients were retreated at or just before 
predicted relapse. Initially, intravenous cyclophospha-
mide was used to accompany the rituximab [10]. Th e 
phase II study showed that cyclophosphamide could be 
replaced by methotrexate or rituximab on its own, 
although the response rates were better when rituximab 
was used in combination with methotrexate. Further, the 
assigned dose of prednisolone was reduced to 60 mg/day 
oral prednisone on day 2 and days 4 to 7 and 30 mg/day 
oral prednisone on days 8 to 14 [11].
Clinical experience of rituximab in SLE
Th e ﬁ rst open, uncontrolled study of rituximab for 
patients with SLE, by Professor Isenberg’s group at 
University College London, showed improvements in 
both clinical and laboratory features of disease following 
treatment with rituximab in refractory SLE [14]; these 
observations have been supported by the publication of 
many other similar open, nonrandomised studies [15-19] 
(Table  1). Th e University College London regimen em-
ployed pre medication with 100  mg intravenous methyl-
prednisolone in addition to 750 mg low-dose intravenous 
cyclo phos pha mide (for renal manifestations) 1 day prior 
to the ﬁ rst of two doses of rituximab, given 2 weeks apart. 
More recently just one dose of cyclophosphamide has 
been used, and any subsequent need for immuno-
suppressive therapy is adjusted based on the merits of 
clinical response and disease manifestation activity that 
can be assessed using well-validated tools such as the 
British Isles Lupus Assessment Group (BILAG) 2004 
index (for example, using the BLIPS computer software 
program; LIMATHON, Sheﬃ  eld, UK).
Appreciating this robust clinical management focused 
on the individual patient  – potentially involving multi-
disciplinary expert opinion, including rheumatologists, 
dermatologists and renal physicians – is important when 
comparing the results with those from large multicentre 
randomised controlled trials with variable quality obser-
vations in a broad population.
Worthy of note is that the indication for rituximab at 
Professor Isenberg’s centre is a combination of active 
disease (renal or nonrenal) (assessed by the BILAG 2004 
index) poorly controlled despite at least two standard 
immunosuppressive agents (not including cortico steroids) 
used for suﬃ  cient time at optimal doses. To date, 100 
patients have been treated at University College London 
with at least one cycle of rituximab and more than 30 
patients have received repeated treatment. Although 
involving only small numbers, the observations from 
repeating the regimen showed that improvements in 
disease, including remission rates, were sustained in 
patients who responded to the initial treatment [20]. Th is 
same group has previously demonstrated following B-cell 
depletion therapy (BCDT) that anti-double-stranded DNA 
(anti-dsDNA) and anti-nucleosome antibodies reduce to 
30 to 40% of baseline, whereas other autoantibodies such 
as anti-Ro and antibodies to pneumococcal poly sac-
charide (protective) remain unaltered. Th is observation 
would suggest that rapidly proliferating clones of B cells 
may give rise to short-lived plasma cells that produce 
these anti-dsDNA, anti-cardiolipin and anti-nucleosome 
antibodies and appear preferentially aﬀ ected by BCDT 
[21], whereas other autoantibodies such as anti-Ro and 
anti-RNP or protective antibodies, which develop follow-
ing immuni sa tion and are thought to be produced by 
long-lived plasma cells, remain unaltered.
In line with this experience, anti-dsDNA antibody 
levels tend to fall but not to normalise and these anti-
bodies are probably produced by a combination of short-
lived and long-lived plasma cells. Similar to these ﬁ nd-
ings, a post-hoc analysis of the EXPLORER trial focusing 
on the biological eﬀ ects of rituximab revealed a signi ﬁ -
cant reduction in the levels of anti-dsDNA and anti-
cardiolipin antibodies and a signiﬁ cant increase in 
complement levels and serum BAFF in the rituximab-
treated group versus placebo. Analysis of the repopu la-
tion dynamics of subsets of B cells identiﬁ ed naïve cells as 
the primary phenotype detected ﬁ rst in circulation; 
however, the phenotype analysis was limited in that 
CD27– memory cells were not examined in this study 
[22]. Th e changes in biological eﬀ ects did not translate 
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into clinical beneﬁ ts at 1  year. Whether a long-term 
follow up with more detailed phenotype analysis at 
various time points would help predict response to 
rituximab therapy is not known. However, designing 
clinical trials to deﬁ ne the precise relationship between 
the biological eﬀ ects that occur following BCDT and the 
clinical response in the long term (typically, 2 to 5 years) 
would be met with the potential challenge of maintaining 
remission in the placebo group with conventional 
immunosuppressants alone. Th e eﬀ ects extend to global 
disease control including an improvement in lipid proﬁ le 
[23], but such beneﬁ ts are not necessarily captured in 
randomised controlled trials with a short duration of 
follow-up.
Recently, following the approach by a group at Imperial 
College (see later) in a pilot study, eight patients with 
active disease were treated at diagnosis with rituximab in 
an attempt to avoid the use of corticosteroids. Using this 
approach it was possible to reduce the cumulative dose of 
steroids substantially in ﬁ ve of the eight patients [24], a 
major long-term advantage.
A recent review of the rituximab experience in approxi-
mately 200 patients with refractory SLE, from open 
studies and real clinical experience, indicated that many 
would respond at least partially to B-cell depletion [25]. 
Diﬀ erences in determining endpoints for these studies 
make it diﬃ  cult to establish formal median and range of 
improvements. In a phase I/II dose-escalation trial of the 
Table 1. Reported effi  cacy of rituximab in nonrandomised trials of systemic lupus erythematosus
   Number of
   patients/ Method of assessment
 Rituximab Organ-specifi c follow-up (mean disease activity score before/after
Study regimen disease (months) B-cell depletion)
Anolik and colleagues [64];  Variable No (7 LN) 17/12 SLAM improved in patients achieving eff ective B-cell
Looney and colleagues [26]     depletion (6.8/5.2)
Leandro and colleagues [15]b 2-dose No (17/19 LN) 19/6 BILAG (13.9/5)
Vigna-Perez and colleagues [65] 2-dose Yes, LN 22/3 Mexico-SLEDAI (10.8/6.8)
Cambridge and colleagues [21]b 2-dose No (12/15 LN) 15/6 BILAG
Tamimoto and colleagues [66] Variable No (4/8LN) 8 SLEDAI (17.6/7.3)
Tokunaga and colleagues [28] Variable Yes, NPSLE 10/7 to 45 Neurological parameters (GCS)
Tanaka and colleagues [67] 2-dose No (6LN) 14/7 BILAG (12.5/7.1)
Ng and colleagues [17]b 2-dose No (21 LN) 32/39 BILAG (13/5)
Reynolds and colleagues [45] Variable No 11/10 BILAG (median reduction of 7.5)
Li and colleagues [68],  2-dose Yes, LN 19/12 SLEDAI (9.2/2.5)
Lu and colleagues [69]b 2-dose No (33/45 LN) 45/39.6 BILAG (12/5)
Pepper and colleagues [56] 2-dose + MMF  Yes, LN 20/12 Renal parameters improved in 14/18 at 12 months
 maintenance 
Catapano and colleagues [19]  4-dose (15) or  No (11 LN) 31/30 BILAG (14.5/3.5 at 24 months)
 2-dose + CYC (16)
Sfi kakis and colleagues [70] 4-dose Yes, LN 10/12 Renal parameters
Gottenberg and colleagues [71] 4-dose No (4 LN) 13/8.3 SLEDAI (8/2)
Smith and colleagues [18] 4-dose, retreated  No 11/24 BILAG (14/2)
 with 2-dose
Gunnarsson and colleagues [72] 4-dose Yes, LN 7/6 SLEDAI (15/3)
Galarza and colleagues [73] 4-dose No  43/12 SLEDAI (12.5/4.5)
Jonsdottir and colleagues [74] 4-dose No (10 LN) 16/27 SLEDAI (12.1/4.7)
Lindholm and colleagues [75] 4-dose No (17 LN) 29/22 Renal parameters
Sutter and colleagues [76] 4-dose No  12 SLEDAI (9/5)
Boletis and colleagues [77] 4-dose Yes, LN  10/38 Renal parameters
Melander and colleagues [78] 4-dose regimen  Yes, LN 20/22 12/20 improved
 (10 retreated)
BILAG, British Isles Lupus Assessment Group; CYC, cyclophosphamide; GCS, Glasgow Coma Scale; MMF, mycophenolate mofetil; SLAM, systemic lupus activity 
measure; LN, lupus nephritis; NPSLE, neuropsychiatric systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index. aRandomised 
controlled trial. bSame cohort in these studies.
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safety and eﬃ  cacy of rituximab in addition to ongoing 
therapy in 18 patients with SLE, three dosing regimens of 
rituximab were studied as follows: six patients received a 
low dose, a single infusion of 100  mg/m2; six patients 
received an intermediate dose, a single infusion of 
375  mg/m2; and ﬁ ve patients received a high dose, four 
infusions of 375 mg/m2 administered 1 week apart. Th ere 
was a signiﬁ cant improvement in the disease activity, as 
measured by systemic lupus activity measure scores, in 
all patients by 2  months, which persisted at 12  months 
regardless of a change in anti-dsDNA anti body and 
complement levels. Six of 17 patients developed human 
anti-chimeric antibodies, resulting in reduced serum 
rituximab levels and ineﬃ  cient B-cell depletion and less 
impressive eﬃ  cacy. Importantly, there were no signiﬁ cant 
adverse events [26]. Th e UK-BIOGEAS registry study of 
164 patients with refractory or relapsing lupus nephritis 
reported a 67% partial or complete response rate to 
rituxi mab using standardised response criteria [27].
Clinicians therefore continue to use rituximab for 
refrac tory lupus nephritis as well as nonrenal manifes ta-
tions including haematological, skin and central nervous 
system manifestations where clinically useful responses 
have been reported [28,29]. Th ere is thus extensive non-
randomised and retrospective experience of rituximab in 
the treatment of refractory SLE. A role for rituximab for 
this indication is supported by the consistency of the 
reports of improvement but diﬀ erences in regimens, 
concomitant medications and endpoints remain, making 
it diﬃ  cult to assess the extent of eﬀ ectiveness of B-cell 
depletion accurately. Additionally, there is uncertainty as 
to how to reduce relapse risk after rituximab, and an 
unqualiﬁ ed recommendation for rituximab in refractory 
SLE will require higher quality evidence.
Safety and effi  cacy in clinical trials
To evaluate the safety and eﬃ  cacy of rituximab in SLE in 
a clinical trial setting, two double-blind, randomised, 
placebo-controlled trials (DBRCTs) investigating renal 
(LUNAR study) and nonrenal (EXPLORER study) mani-
fes tations were undertaken (Table  2). Both trials 
addressed the hypothesis that the addition of rituximab 
to the standard of care, corticosteroids and immuno sup-
pres sants was superior to addition of placebo for the 
control of SLE activity.
In the EXPLORER study, the safety and eﬃ  cacy of 
rituximab in moderate-to-severe active nonrenal SLE 
was evaluated [30] (Figure  1). Th is study included 257 
patients with ≥1 BILAG  A score (>50% of patients at 
entry) or ≥2 BILAG B scores despite ongoing stable-dose 
immuno suppressant therapy with either azathioprine 
(100 to 250  mg/day), mycophenolate (1 to 4  g/day) or 
metho trexate (7.5 to 25 mg/week), which was continued 
during the trial. Background immunosuppressive therapy 
was evenly distributed. A key feature of treatment in this 
study was the additional course of high-dose cortico-
steroids patients received early in the study. Cortico steroids 
were given at initial doses of 0.5  mg/kg, 0.75  mg/kg or 
1  mg/kg depending on severity (by BILAG score) and 
type of disease manifestations, followed by a taper 
regimen. Of the overall population, >50% were classed as 
steroid dependent, and ≥60% of patients received an 
average 45.9 ± 16.4 mg prednisolone and then attempted 
to reduce to a target dose of <10 mg/day over the 10-week 
taper period and ≤5 mg/day at week 52.
Patients were randomised at a ratio of 2:1 to receive 
rituximab (1,000  mg) or placebo. Eighty-eight patients 
received placebo and 169 patients received rituximab 
(two doses given 14  days apart) on days  1, 15, 168, and 
182. Th e majority (≥50%) of patients in both groups had 
musculoskeletal and mucocutaneous disease.
Th e primary endpoint of the EXPLORER study was 
stringent, with complete and partial response deﬁ nitions 
as follows.
To classify as a complete/major response, at week 24 an 
improvement in all organ systems with a BILAG C score 
or better was required. Further, this response was to be 
sustained at week  52, without experiencing a severe or 
moderate/severe ﬂ are during the period to week 24 and 
week  52, respectively. A severe ﬂ are was deﬁ ned as a 
BILAG  A score or as two new domains with BILAG  B 
scores [31].
Patients were considered to have attained a partial 
response if: there was an improvement in all organ 
systems with a BILAG  C score or better, which was 
sustained for 16 consecutive weeks; a BILAG B score in 
no more than one organ system at week 24 without a new 
BILAG  A or BILAG  B score to week  52 was achieved; 
and, at week 24, no more than two BILAG B scores were 
achieved without new BILAG  A or BILAG  B scores 
provided the baseline BILAG score was one A score plus 
≥2 B scores, ≥2 A scores, or ≥4 B scores.
Th e secondary endpoints included the time-adjusted 
area under the curve minus the baseline BILAG score 
over 52 weeks, the proportion of patients who achieved a 
major and partial clinical response, the proportion of 
patients who achieved a BILAG  C score in all organ 
systems at week  24, the time to the ﬁ rst moderate to 
severe disease ﬂ are, improvement in quality of life as 
measured by the Lupus Quality of Life, and the propor-
tion of patients who achieved a major clinical response 
with a prednisolone dose <10  mg/day from week  24 to 
week  52. In addition, serological activity parameters 
including levels of autoantibodies, complement, immuno-
globulins, T-cell and B-cell counts and human anti-
chimeric antibody were monitored.
In the intent-to-treat analysis of 257 patients, approxi-
mately 70% of patients completed the study in both arms 
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and the safety and tolerability was similar in both groups. 
Th ere was no diﬀ erence between the addition of placebo 
and rituximab to the standard of care in the primary and 
secondary eﬃ  cacy endpoints, including the BILAG-
deﬁ ned response, in terms of both area under the curve 
and other analyses.
A preplanned subgroup analysis, however, detected a 
beneﬁ cial eﬀ ect of rituximab in the primary endpoint in 
the African American and Hispanic patients, a major 
clinical response in 13.8% and a partial response in 20% 
when compared with 9.4% and 6%, respectively. Notably, 
these patients had more active disease and more 
refractory disease as previously reported [32]. Th ere were 
signiﬁ cant biological eﬀ ects in the rituximab-treated 
group, with greater falls in anti-dsDNA levels and rises in 
complement levels compared with placebo. Interestingly, 
up to 9.5% of patients did not achieve complete B-cell 
depletion, but analysis without these patients did not 
change the primary outcome. Th is phenomenon has been 
observed in autoimmune prone mice [33,34]. A recent 
study investigating the role of highly sensitive ﬂ ow 
cytometry detected a correlation between clinical 
response and B-cell numbers [35].
Th e LUNAR study investigated the safety and eﬃ  cacy 
of 2  ×  1,000  mg rituximab, at both 0 and 6  months, as 
compared with placebo in addition to background therapy 
with high-dose glucocorticoids and mycophenolate 
mofetil 3  g/day in 144 patients with proliferative lupus 
nephritis, classes III and IV (Figure 2).
Th e primary endpoint of the study was the proportion 
of patients with a complete or partial remission of 
nephritis at 12 months. Complete response was deﬁ ned 
as, at week  52: serum creatinine improving from ab-
normal to normal level or from normal to ≤115% of 
baseline normal; a fall in the urine protein–creatinine 
ratio to <0.5; and urine sediment containing <5 red blood 
Table 2. Summary of the randomised-controlled trials of rituximab therapy in systemic lupus erythematosus
Study Rituximab regimen Concomitant therapy Endpoints Results
LUNAR Randomised 1:1 to receive 
either rituximab or placebo 
on days 1, 15, 168, and 182
MMF and corticosteroids Primary: (i) % patients with 
complete or partial renal 
responses at week 52. 
Secondary: (ii) patients with 
BL UPCR >3 to UPCR <1; 
(iii) % change from BL in 
anti-dsDNA; and (iv) mean 
change from BL in C3 (mg/
dl)
(i) and (ii) no signifi cant diff erence; (iii) placebo 
(50%) and rituximab (69%) (P <0.01); and (iv) 
placebo (25.9%) and rituximab (37.5%) (P <0.03). 
% patients requiring a new immunosuppressive 
agent placebo (11.1%) and rituximab (1.4%)
EXPLORER Randomised 1:2 to receive 
placebo or rituximab, 
methyl prednisolone 
100 mg and acetaminophen 
and diphenhydramine or 
placebo on days 1, 15, 168, 
and 182
Usual dose prednisolone 
and either azathioprine 
100 to 250 mg/day, MMF 
1 to 4 g/day or MTX 7.5 
to 27.5 mg/week, and 
additional prednisolone 
(0.5 mg/kg, 0.75 mg/kg, 
or 1.0 mg/kg), tapered 
beginning on day 16 to 
a dosage of 10 mg/day 
over 10 weeks and 5 mg/
day by week 52
Primary: eff ect of placebo or 
rituximab in achieving and 
maintaining a major, partial 
or no response at week 52 
in each of the eight BILAG 
index organ system scores. 
Secondary: described earlier
Primary EP: major clinical response 15.9% vs. 12.4% 
and PCR 12.5% vs. 17.2% for placebo and rituximab, 
respectively. In the African American/Hispanic 
group: major clinical response 9.4% vs. 13.8% and 





Randomised to receive 
either rituximab or a 
combination of rituximab 
and cyclophosphamide 
750 mg on day 1 and day 
15, followed by intravenous 
methylprednisolone 250 mg 
and oral prednisolone 
30 mg from day 2 to day 5, 
then 0.5 mg/kg for 4 weeks 
and then reducing the dose 
by 5 mg every 2 weeks to 
5 mg/day
Other medications were 
stopped except for 
hydroxychloroquine, oral 
prednisolone and statins. 
All patients also received 
angiotensin-converting 
enzymes inhibitors
Primary: in each of the 
groups, % patients with 
complete response at week 
48. Secondary: % patients 
with partial response; and 
duration of complete CD19+ 
B-lymphocyte depletion, 
histological assessment, 
adverse eff ects or death at 
week 48
Primary EP: no signifi cant diff erence between 
the two groups. Overall, at week 48, 21% had a 
complete response, 58% achieved partial response, 
11% remained the same and 11% worsened. 
Secondary EP: 42% patients achieved a complete 
response; 95% achieved eff ective depletion; no 
signifi cant diff erence in the proportion of patients 
achieving a complete depletion at weeks 4, 8, 24 
and 48 between the two groups except at week 2; 
a signifi cant improvement in mean serum albumin 
levels (28.1 to 39.4), changes in the concentration 
of serum C3 (0.55 to 0.85), dsDNA antibody (693 to 
8) and immunoglobulins. At week 48, the urinary 
protein excretion improved and there was an 
improvement in the ESR (62.1 to 30) and SLEDAI 
(9.2 to 2.5)
BL, baseline; EP, endpoint; ESR, erythrocyte sedimen tation rate; MMF, mycophenolate mofetil; MTX, methotrexate; PCR, partial clinical response; SLEDAI, Systemic 
Lupus Erythematosus Disease Activity Index; UPCR, urine protein creatinine ratio.
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cells in a high-power ﬁ eld without casts. Patients who did 
not meet complete response were considered to have 
achieved a partial response if: serum creatinine reduced 
to ≤115% of abnormal baseline; the number of red blood 
cells/high-power ﬁ eld reduced to ≤50% baseline without 
red blood cell casts; and a reduction in urine protein–
creatinine ratio from ≥3.0 to ≤3.0 or to <1 from ≤3.0.
Th e secondary endpoints were: complete renal res-
ponse sustained from week  24 to week  52; time to ﬁ rst 
complete renal response; and, at week  52, the urine 
protein–creatinine ratio improving from >3 to <1, the 
time-adjusted area under the curve minus the BILAG 
global score, and a change in the physical function of SF-
36 health survey. As in the EXPLORER study, serological 
Figure 1. Treatment protocol of the BELONG study. AZT, azathioprene; CYC, cyclophosphamide; EL, EUROLUPUS; LN, lupus nephritis; MMF, 
mycophenolate mofetil; OCR, ocrelizumab; ORR, overall renal response; PBO, placebo.
Figure 2. Treatment protocols of the EXPLORER and LUNAR studies. (a) EXPLORER study. (b) LUNAR study. BILAG, British Isles Lupus Assessment 
Group; ISN/RPS, International Society of Nephrology/Renal Pathology Society; MMF, mycophenolate mofetil; MTX, methotrexate; Rx-AZA, treatment 
with azathioprine.
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indices, human anti-chimeric antibodies and B-cell 
depletion were monitored.
Th e response rates for rituximab and placebo were 26% 
and 30% for complete renal response and 30% and 15% 
for partial renal response, respectively. At week 52, more 
patients in the placebo arm (8  patients vs. 0  patients) 
received rescue cyclophosphamide therapy. Improvement 
in proteinuria was 32% and 9% for rituximab and placebo, 
respectively. Analogous to the ﬁ ndings in the EXPLORER 
study and the ALMS trial, a greater proportion of black 
patients responded favourably, although this was not 
statistically signiﬁ cant. Th ere was a greater reduction in 
anti-dsDNA levels in the rituximab-treated group. 
Whether the response noted in patients of African 
ancestry is attributable to the disease severity alone or 
whether there are potential diﬀ erences in B-cell 
responsiveness to rituximab therapy in these patients is 
as yet unclear. In this respect, it is worth noting that 
ethnicity might inﬂ uence the clinical response to 
treatment even with conventional immuno suppressants 
as noted in the ALMS study. Our own data (D Isenberg, 
unpublished observations) has not indicated a clearly 
diﬀ erent outcome at 12  months post BCDT comparing 
Caucasians, Afro-Caribbean or Asian patients. Drawing 
any ﬁ rm conclusions based on the disease severity alone 
would therefore be diﬃ  cult.
However, overall this was a negative study in that there 
was no signiﬁ cant diﬀ erence between the rituximab 
group and the placebo group. Th e absolute diﬀ erence in 
response was 11%, with 54% and 43% responding in the 
rituximab and placebo groups, respectively [36]. Th is 
value was less than the planned 23% diﬀ erence, which in 
retrospect looks over-optimistic especially considering 
the analysis at only 12 months in this population. Again, 
diﬀ erences in serological markers between groups were 
found and a subsequent analysis found greater falls of 
proteinuria in the rituximab group. More African patients 
in the rituximab group responded and cyclophosphamide 
rescue was required more frequently in the placebo 
group. Th erefore, despite some clear signals of eﬃ  cacy 
and safety, this study did not meet its primary or 
secondary endpoints.
Why did these two DBRCTs fail to meet their endpoints?
As discussed earlier, there are several confounding 
factors that may have masked the ability to accurately 
quantify any signiﬁ cant clinically meaningful beneﬁ cial 
eﬀ ects of rituximab (Table  3), perhaps the most impor-
tant being the aggressive background immuno sup-
pressive therapy in the placebo and rituximab-treated 
groups. High-dose corticosteroids, in particular, may 
have prevented the full extent of eﬃ  cacy of rituximab 
becom ing evident, a factor that warrants due consider a-
tion in the design of future clinical trials for any 
investigational agent. Th e dilemma for trial designers is 
how rapidly to reduce glucocorticoid in patients with 
organ-threatening SLE. Trials with duration beyond 12 
months would have greater chance of demonstrating the 
speciﬁ c treatment eﬀ ect that could be attributed to 
rituximab if corticosteroids are reduced to low levels 
during the ﬁ rst 6  months. Corticosteroid dosing could 
also be included in the threshold for res ponse in trial 
endpoints. For example, standard treatment should allow 
low-dose prednisolone and the proportion of patients 
requiring >7.5 mg/day prednisolone could be classed as a 
failure. In the open studies, response was deﬁ ned with 
such stringent criteria. Furthermore, apply ing such 
criteria would not detect organ-speciﬁ c improve ment; 
for example, a signiﬁ cant sustained improvement in a 
severe haematological abnormality but concurrent minor 
or moderate ﬂ are in skin or muco cutaneous disease 
would be classiﬁ ed as a failure.
Th e planned eﬃ  cacy margin in the LUNAR study was 
inﬂ uenced by the 55% complete and partial response rate 
in the ALMS trial at 6 months using either myco pheno-
late or cyclophosphamide and corticosteroids. Th is 
suggested that 45% did not respond to standard of care; 
however, reasons for failure in the ALMS trial included 
death, severe adverse events, drug intolerance and 
patient/physician preference. One can estimate that true 
treatment failure was closer to 25% than 45%. A further 
factor in nephritis trials is the delayed response of the 
outcome measure, proteinuria, to reduction in histo-
logical activity in the kidney. Th e true time to remission 
of proteinuria is up to 2  years. Had the LUNAR trial 
aimed for a 12% eﬃ  cacy diﬀ erence and involved a 2-year 
duration, the study may have met its endpoint despite a 
small sample size.
One should also note that to date there is insuﬃ  cient 
evidence to support the routine use of rituximab therapy 
for patients with speciﬁ c neuropsychiatric manifes ta-
tions. However, in a study of 10 patients with a range of 
neuropsychiatric manifestations (including cognitive dys-
func tion, psychosis and seizures) refractory to conven-
tional immunosuppressants, including intravenous cyclo-
phos phamide, there was a signiﬁ cant improvement, 
measured by the Systemic Lupus Erythematosus Disease 
Activity Index score at 28 days after treatment with 
rituximab, in all patients  – and in ﬁ ve patients the 
response lasted for more than 1 year [28].
Th e other anti-CD20 mAb investigated in clinical trials 
for SLE is ocrelizumab (a humanised anti-CD20 mAb). In 
rheumatoid arthritis, ocrelizumab (two regimens used: 
200 mg and 500 mg ×2 every 6 months) was eﬀ ective in 
reducing signs and symptoms and joint damage when 
added to a stable dose of methotrexate [37,38]. However, 
a detailed analysis of results from four DBRCTs investi-
gat ing the safety and eﬃ  cacy of ocrelizumab for RA 
indicated that an increase in serious infections associated 
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with ocrelizumab compared with placebo were dose 
depen dent and occurred more frequently in Asia 
(particu larly Japan) [39].
Two simultaneous clinical trials were initiated to study 
the safety and eﬃ  cacy in lupus. Ocrelizumab was dosed 
diﬀ erently from the RA and the rituximab SLE studies, at 
either 400 or 1,000  mg intravenously ×2 at entry with 
repeat, single dosing every 4 months. Th is regimen was 
designed to induce and maintain B-cell depletion 
throughout the trial periods. Th e BEGIN study for 
nonrenal SLE was can celled early. Th e BELONG study 
for proliferative lupus nephritis compared 1,000  mg or 
400 mg ocrelizumab at 1 day and 15 days, then repeated 
with a single dose every 4  months on a background of 
high-dose glucocorticoids and either mycophenolate 
mofetil or cyclophosphamide dosed according to the 
EUROLUPUS protocol (Figure  1). Although the study 
was designed to continue for to at least 2  years, the 
primary endpoint was the proportion of patients achiev-
ing partial or complete nephritis remission at 48 weeks. 
A total of 381 patients were recruited before the trial was 
stopped early due to an imbalance in the rate of serious 
infections in the ocrelizumab patients receiving myco-
phenolate. Th e 221 patients who had passed the 32-week 
treatment point were assessed. Th e absolute diﬀ erence in 
renal response was 12%, with 63% and 51% for the 
combined ocrelizumab and placebo groups prospectively. 
However, it is worth noting that in the subgroup analysis 
there was a greater treatment eﬀ ect of ocrelizumab when 
combined with the EUROLUPUS cyclophosphamide 
regime (renal response of 65.7% for ocrelizumab vs. 
42.9% for EUROLUPUS alone) than with mycophenolate 
mofetil (renal response of 67.9% for ocrelizumab vs. 61.7% 
for mycophenolate alone), which was largely ex plained by 
Table 3. Potential explanations for the apparent discrepancy in clinical response reported in clinical experience and 
DBRCTs
 Clinical experience Randomised controlled trials
Disease activity Refractory to conventional immunosuppressants Rituximab was used as an add-on therapy to background 
immunosuppressants
Favourable response reported in life-threatening cases, 
often including a range of organ-system involvement such 
as CNS manifestations, cytopenias and others
Life-threatening cases and those with CNS manifestations 
were not evaluated in controlled trials. This setting warrants a 
dedicated study
Clinical response No defi ned pretreatment, therefore complete and partial 
responders might not be clearly distinguished
Predefi ned endpoints were stringent, perhaps driven by 
the impressive responses seen in clinical experience in an 
uncontrolled setting
Improvement in one system alone might qualify for 
response, regardless of a fl are or lack of response in another 
organ system
Predefi ned and usually stringent. For example, despite clinical 
response and steroid-sparing eff ect, a reduction in proteinuria 
that does not meet the predefi ned threshold would not 
qualify as complete/partial response
Background 
immunosuppressants
Flexibility in changes to background immunosuppressants 
including the dose of corticosteroids
Changes to or deviation with predefi ned background therapy 
would qualify as nonresponder
Concomitant use of large dose of steroids is uncommon Concomitant use of large dose of corticosteroids might have 
limited any benefi cial eff ects of rituximab, the extent of which 
may be more restricted in such a setting than previously 
assumed
Rituximab dosing-regimen Variable between reports Predefi ned dosing regimen
Steroid tapering Steroid-sparing eff ect is not a requirement to defi ne 
response and therefore favourable response might be 
overestimated
Steroid dosing eff ect was included in the defi nition of clinical 
response 
Adverse events No standardised reporting of adverse events. Therefore, the 
true incidence of serious adverse events in clinical practice 
is not comparable with that reported in other uncontrolled 
studies or controlled clinical trials
Rituximab therapy appears to be safe as no there were 
no signifi cant diff erences in serious adverse events when 
compared with standard-of-care treatment
Follow-up period Not defi ned, therefore it is not known how many 
responders had sustained response in the long term
Predefi ned, therefore, unless long-term studies are 
undertaken, it would be diffi  cult to detect the importance of 
eff ects seen at relatively short-term follow-up
CNS, central nervous system.
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a higher response rate in general with myco phenolate 
mofetil whilst perhaps again reﬂ ecting the outcome seen 
with rituximab in the LUNAR study [40] (Table 4).
Eﬃ  cacy of the BCDT has also been demonstrated in 
another autoimmune condition, relapsing–remitting 
multiple sclerosis. A recent phase II randomised clinical 
trial investigating the safety and eﬃ  cacy of ocrelizumab 
(given together with pre-infusion steroids only) in 
multiple sclerosis showed a signiﬁ cant reduction in 
neurological lesions compared with placebo as assessed 
by gadolinium-enhanced magnetic resonance images. 
Serious adverse events occurred in three of 55 patients 
receiving 2,000  mg ocrelizumab (one of 55 patients 
receiving 600  mg ocrelizumab, and two of 54 patients 
each in the placebo group and the IFNβ-1a group) [41]. 
Th ese results also support the notion that treatment 
regimens of BCDT continue to have the potential to be 
safe in the wider context of treatment for chronic 
refractory auto immune diseases.
Although not the principal focus of this review, it is 
notable in two trials involving >800 patients in each trial 
that belimumab (Benlysta), an anti-BLyS antibody, met 
its primary endpoint with a 10% and 14% absolute 
response diﬀ erence over placebo [42,43]. Th e primary 
Table 4. Safety and effi  cacy of ocrelizumab in lupus nephritis: design and results of the BELONG study
Patients and methods Concomitant therapy Endpoints Results
A total of 381 patients with class III or 
class IV (80%) LN were randomised 
equally to receive either: placebo, 
OCR 400 mg or OCR 1,000 mg 
on days 1, 15 and every 16 weeks 
thereafter, >74% received three 
infusions and >50% received four 
infusions
In addition, either: MMF up to 3 g/
day (63%); or EL (cyclophosphamide 
500 mg ×6/2 weeks) followed by 
azathioprine 2 mg/kg up to 200 mg/
day; and a steroid taper regimen – 
intravenous steroids: allowed up to 3 
g by day 15, given in divided pulses), 
oral steroids: 0.5 to 0.75 mg/kg (≤60 
mg/day) with taper to ≤10 mg over 
10 weeks
Complete renal response: normal 
serum creatinine and ≤25% higher 
than baseline; urinary protein to 
creatinine ratio <0.5; inactive urinary 
sediment
In all modifi ed intention-to-treat 
populations, there was a treatment 
diff erence of 12.2% with 54.7% vs. 
66.9% for placebo (n = 75) and OCR 
(n = 148) groups, respectively
Partial renal response: serum 
creatinine ≤25% above baseline 
value; and 50% improvement in the 
urine protein to creatinine ratio, and 
if baseline ratio >3.0 then a urine 
protein to creatinine ratio <3.0
ORR higher in OCR (400 mg) + EL 
(65.6%) and OCR (1,000 mg) + EL 
(74.2%) groups vs. placebo + EL (42.9%), 
ORR was similar in OCR+ MMF (67.9%) 
vs. placebo + MMF (61.7%)
Nonresponse: not achieving either a 
complete or partial renal response. 
Patients who died or discontinued 
the study prior to week 48 (and 
had no renal data within 12 weeks 
of week 48) were considered 
nonresponders
≥50% reduction in urine protein-to-
creatinine ratio occurred in 69.6% vs. 
58.7 % for OCR and placebo groups, 
respectively
Urine protein-to-creatinine ratio <0.5 
was achieved in 39.9% vs. 37.3% for 
OCR and placebo, respectively
Serious adverse eff ects imbalance 
appeared to be driven by the 
combination with MMF: OCR 400 mg 
(41.8%) compared with 1,000 mg OCR 
+ MMF (24.1%) and placebo + MMF 
(21.3%). Serious adverse event rates in 
EL groups were not reported as higher 
in the OCR arms
Serious infection imbalance appeared 
to be driven by the OCR combination 
with MMF. MMF groups: OCR 400 mg 
(32.9%) compared with 1,000 mg OCR 
(19%) and placebo + MMF (16.3%). EL 
groups: OCR 400 mg (12.8%) compared 
with 1,000 mg OCR (10.4%) and 
placebo + MMF (11.1%)
EL, EUROLUPUS regimen (cyclophosphamide followed by azathioprine); LN, lupus nephritis; MMF, mycophenolate mofetil; OCR, ocrelizumab; ORR, overall renal 
response.
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endpoint was a composite score, the SLE Responder 
Index, comprising a fall in Systemic Lupus Erythematosus 
Disease Activity Index of 4 points, no new BILAG A or B 
scores, and no change in the physician’s global assess-
ment. Th e compari sons were made at the start of the 
study, and at 52 or 76 weeks. Th ese studies demonstrate: 
the need for larger trials looking for small but meaningful 
treatment eﬀ ects; the potential eﬃ  cacy of B-cell-targeted 
therapy; a similar magnitude of response to that seen in 
the LUNAR and BELONG studies, which collectively 
raises the question of deﬁ ning a clinically meaningful 
treatment eﬀ ect in SLE trials; and a new approach to 
deﬁ ning a primary endpoint, the SLE Responder Index.
Lessons learned so far and future clinical trial 
design – how to get it right?
Th e failure of clinical trials in SLE has introduced palpable 
uncertainty whilst providing some invaluable lessons 
regarding expectations for potential new thera pies, 
carefully planned trial designs and appropriate endpoints 
for the particular agent/regimen in question. It is relevant 
to note that most preliminary data used rituximab for 
refractory SLE when standard agents had failed. Th is is in 
contrast to the randomised trials, which added rituximab 
on top of standard therapy for non refractory patients. 
Several factors speciﬁ c to SLE increase the complexity in 
designing successful trials. RA is a less heterogeneous 
disease and is much better under stood when compared 
with SLE and when arthritis is the main manifestation, 
despite the potential for other organs to be involved. 
Moreover, there exists a good deal more standardisation 
for clinical trials including validated endpoints  – for 
example, Disease Activity Index, 28-joint Disease Activity 
Score. Conducting large-scale studies in a relatively short 
period of time is therefore possible – particularly as RA is 
more common and patient access is better, making 
statistically powered studies of relatively short duration 
feasible. For lupus, including nephritis, we are still some 
distance from achieving the same level of understanding 
and standardisation in the clinical trial setting.
In an attempt to improve the lupus patient’s great 
unmet need, the European League Against Rheumatism 
has made a few suggestions to help researchers design 
successful trials [44]. Th e main points for the future 
design of clinical trials are to use strictly evaluated (a 
surrogate of therapeutic success against mortality or end-
organ failure) outcome measures, including the disease 
activity indices, and to follow a standardised approach 
towards recording adverse events that could be used to 
measure beneﬁ t-to-risk ratios from interventions, com-
parable between trials. Increasingly important in future 
trials, when comparing the interventional drugs, is the 
real diﬀ erence there may be in their potential to cause 
harm in the long term.
Th e aims of randomised controlled trials are to be 
deﬁ ned to test robust hypotheses generated based on the 
available evidence from the open studies and clinical 
experience. Further, careful attention needs be paid when 
considering important factors, patient selection and 
sample size, the therapeutic agent or regimen and its 
potential eﬀ ectiveness (and meaningful treatment delta 
vs. control), the disease outcome measures and disease 
activity indices, adequate follow-up and the adverse 
events (Tables 5 and 6). Th ese variable factors contribute 
to a great element of uncertainty in predicting the 
probability of the success of clinical trial design in SLE.
Patient selection and sample size
From a clinical trial design point of view, there are 
important diﬀ erences in the patient cohort, the treatment 
regimen and the outcome measures used in open studies 
and real clinical experience when compared with the 
DBRCTs.
Firstly, the patient cohort in open studies and in clinic 
experience, at the time of rituximab treatment, had 
moderate-to-severe disease activity and most had failed 
conventional immunosuppressants (standard of care). In 
contrast, patients participating in the two DBRCTs 
(EXPLORER and LUNAR studies) had active disease, but 
patients who had failed conventional therapy (cyclo phos-
phamide and calcineurin inhibitors) were excluded. 
Further, patients with central nervous system manifes ta-
tions and severe organ-threatening conditions were 
excluded  – situations in which rituximab has demon-
strated a favourable record in the open studies [28,45-47]. 
Capturing the variability in organ-speciﬁ c outcomes for 
diﬀ erent interventions tested is important. For example, 
rituximab may be a better choice than other conventional 
immunosuppressants when both renal and haematolo gi-
cal abnormalities co-exist. A favourable clinical response 
is more likely in seropositive patients. However, we have 
previously noted that anti-Sm positivity and/or a low C3 
level at the time of treatment is associated with a 
reduction in the likelihood of sustained beneﬁ t from B-
cell depletion, and again suggest there is much work to be 
done to understand lupus disease and factors that may 
inﬂ uence the design, population and, ultimately, the 
outcome of clinical trials [48].
The therapeutic agent and the regimen
Rituximab has been mainly been used to achieve B-cell 
depletion in two regimens, either as two doses of 
1,000 mg given 2 weeks apart (two-dose regime, commonly 
used in SLE and RA) or as four doses of 375 mg/m2 (four-
dose regime, most common regime used in lymphoma, 
paediatric autoimmune diseases) given 1 week apart 
(ocrelizumab in SLE moved on from this to initial doses 
2  weeks apart followed by a single infusion every 4 
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months to achieve and sustain B-cell depletion). Notably, 
a systematic review of the clinical experience of rituximab 
for the treatment of refractory SLE suggests that the 
lymphoma regimen (four doses, 375 mg/m2, given 1 week 
apart) may be more eﬀ ective in achieving an improve-
ment in disease than the two-dose regimen (two doses 
given 2  weeks apart) [49]. Based on this review alone, 
however, it is diﬃ  cult to draw ﬁ rm conclusions about the 
relative eﬃ  cacy of either regimen. Catapano and 
colleagues, using both regimens of rituximab for the 
treatment of refractory SLE, although not in a formal 
comparative setting, did not detect a signiﬁ cant diﬀ er-
ence in either the degree of B-cell depletion or clinical 
outcomes [19]. Th e two-dose regimen, more convenient 
for patients requiring just the two hospital infusion visits, 
is therefore preferred.
Deﬁ ning standard treatment used in the comparative 
arm is important, because not doing so would allow 
generous use of other immunosuppressants – particularly 
corticosteroids, which are highly eﬀ ective but associated 
with unacceptable adverse eﬀ ects in the long term, not 
necessarily identiﬁ ed in clinical trials with short-term 
follow-up.
It would be interesting to take a treatment-to-target 
approach to achieve an adequate degree of B-cell deple-
tion and clinical response. For example, evidence 
suggests that the eﬃ  cacy depends on the extent of B-cell 
depletion in RA [50]. Several research groups have noted 
that the degree of B-cell depletion is variable in SLE and 
that early repopulation is common in patients with a 
poor response to rituximab [35]. Th e underlying reasons 
for the variability in B-cell depletion remain elusive. A 
polymorphism in Fcγ receptor IIIa has been shown to be 
important in achieving an adequate degree of B-cell 
depletion, in favour of the high-aﬃ  nity genotypes Fcγ 
receptor IIIa V158F (V, valine; F, phenylalanine) [51]. Treat-
ment-to-target would therefore seem a rational approach 
to take in an attempt to improve the major clinical 
response. However, some patients will probably require 
more frequent doses than others. One approach could be 
to counterbalance this variation using alterna tive dose 
regimes; for example, using two 500  mg doses given 
2  weeks apart, as in a recent trial in RA that reported 
equal eﬃ  cacy, safety and tolerability between the two 
regimes using 500 mg or 1 g, provided adequate depletion 
was achieved [50,52]. Diﬀ erent dosing regi mens could 
poten tially have considerable implications: ﬁ rst, patient 
con venience, with a four-dose regimen requiring more 
hospital visits; second, a very-low dose regimen has been 
associated with the development of anti-drug antibodies 
in SLE while a medium dose (500 mg rituximab ×2) has 
been shown to be adequate in a number of patients with 
RA [50]; and, ﬁ nally, cost-eﬀ ectiveness of BCDT. In this 
respect, it has been noted that rituximab might be rapidly 
consumed in some patients, more frequently in SLE than 
RA [53]. Th is consumption would consequently reduce 
serum rituxi mab levels and may reduce clinical eﬃ  cacy.
Taking experience from ocrelizumab therapy in lupus, 
careful consideration is also necessary when designing 
studies to test the safety and eﬃ  cacy of B-cell-targeted 
approaches, including depletion in patients with active 
disease also taking mycophenolate. A combination of 
ocrelizumab and recently commenced mycophenolate 
Table 5. Adverse events reported in published studiesa 
during or after rituximab-induced B-cell depletion therapy
Infections Pneumoniab
 Shinglesb
 Thigh abscess, subcutaneous abscess




 Streptococcal viridans infection
 Necrotising fasciitis
 Fatal histoplasmosis 
Haematological Neutropeniab
Pulmonary  Pneumonia
 Pulmonary haemorrhage 








 Transient ischaemic attack




 Serum sickness reaction
 Hypogammaglobulinaemia 
 Anaphylaxis





aSee Table 1. bFrequently reported adverse event. cLife-threatening 
complications.
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does not appear to result in a meaningful additive 
response and results in an increased risk of infection 
adverse events (whether the combined impact on the B-cell 
population of anti-CD20 and mycophenolate was a 
contributory factor is not understood), whereas this was not 
the case when used in combination with the EUROLUPUS 
cyclophosphamide followed by azathio prine regimen.
Deﬁ ning the standard of care in the placebo arm is 
important to allow detection of the eﬃ  cacy for the 
intervention tested. For example, in the placebo arm a 
patient with disease activity requiring >7.5 mg predniso-
lone being classed as a failure will allow detecting the 
steroid-sparing eﬀ ect of the intervention, a major advan-
tage in the long term. Th e question has been raised as to 
whether to use rituximab in combination with cyclo-
phosphamide, aza thio prine or mycophenolate, but there 
are some conﬂ ict ing data [19,54]. Th e deﬁ nitive answer is 
therefore awaited.
Another conundrum not yet fully resolved is whether 
there really is added beneﬁ t in using repeated rituximab 
infusions on a regular basis (that is, maintenance therapy) 
or whether it is preferable to repeat B-cell depletion only 
when the patients relapse. A concern about repeated 
infusion is the potential occurrence of hypogamma-
globulinaemia. Information from studies in patients with 
RA (J Edwards, personal communication) suggests that 
many patients begin to drop their IgG levels after annual 
rituximab infusions, particularly in patients with low 
baseline IgG levels [55]. Comparative data for SLE 
patients are awaited.
Clinical evidence for rituximab use – early disease or 
chronic refractory disease?
Limited evidence from two studies is worth considering. 
Firstly, as discussed, when used early in conventional 
immunosuppressive naïve disease, rituximab seems to be 
Table 6. Challenging areas in trial design and possible options
Patient selection and sample size
• Exclude seronegative patients
• Defi ne the disease activity using a validated disease activity index
• Defi ne refractory disease as either failure to respond to one or more immunosuppressants and an assigned dose of corticosteroids 
• Ensure adequate sample size based on statistical power calculation to allow detection of even small therapeutic eff ects
• Allow for proportional representation of patients taking into account factors such as race, age, the duration of disease and type of organ involvement. 
 For example, diff erent histological types of nephritis may have variable sensitivity to B-cell depletion therapy
B-cell depletion
• Standardise the defi nition of adequate degree of B-cell depletion; for example, <5 cells/μl
The treatment protocol and the rituximab regimen
• A randomised trial of adequate sample size to distinguish whether the two-dose or four-dose regimen ± cyclophosphamide is eff ective at achieving an 
 eff ective B-cell depletion and a favourable clinical response
• Determine an appropriate time to retreat 
• Using a standard rituximab regimen would allow for a better comparison between trials
Standardising concomitant therapy
• Classify a change in concomitant immunosuppressant therapy >25% above baseline as partial failure and >50% as complete failure 
• Defi ne an increase in the dose of prednisolone >7.5 mg as partial failure and >30 mg as complete failure
Choosing the right disease activity index
• Choosing an index that is validated and is able to capture organ-specifi c changes: SLE Responder Index and British Isles Lupus Assessment Group, 
 respectively
Defi ning the endpoints
• Defi ne practically achievable primary endpoints, based on a pilot study and/or taking into account the predicted failure rate for the defi ne cohort, which 
 would detect even small therapeutic benefi t
• Defi ne both clinical and nonclinical parameters in the secondary endpoints 
• Assess steroid-sparing eff ect. For example, allow only low-dose prednisolone <10 mg/day and any clinical requirement to increase the dose by >50% as 
 partial failure and >100% as complete failure
Duration of follow-up
• The duration of follow-up should be defi ned to allow capture of both early and late eff ects including both safety and effi  cacy of the therapeutic 
 intervention. 
• Defi ning the adverse events
The reporting of adverse events could be standardised adhering to the OMERACT-recommended guidance [63]
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eﬀ ective and has a steroid-sparing eﬀ ect [24]. Further, 
Pepper and colleagues have prospectively analysed the 
response to rituximab for biopsy-proven lupus nephritis, 
where a total of 14/18 (78%) patients achieved a complete 
or partial remission with a sustained response in 12/18 at 
1 year (67%), with two patients having a relapse with an 
increase in proteinuria. Th ere was a reduction in predni-
so lone usage from a mean of 10 mg to 5 mg at 2 years, six 
patients stopped, six patients managed to reduce the 
dose and the remaining were maintained on the same 
dose. Five patients required a temporary increase for 
extra-renal manifestations [56].
Defi ning the outcome measures and clinical response
Clinical outcome measures are to be deﬁ ned based on 
evidence, taking into account the probability of detecting 
change given the expected natural progress of the organ-
speciﬁ c disease manifestations in an appropriate time-
frame (potentially in contrast to the artiﬁ cial time points 
used in clinical trials). In parallel, it is important to 
include the biomarkers that predict disease activity and 
outcomes in SLE. For example, there are a few validated 
outcome measures that predict end-stage renal disease; it 
has been shown that doubling of serum creatinine [57,58] 
and persistently elevated serum creatinine at 48 weeks 
[58] is predictive of end-stage renal disease. Another 
routinely available biomarker in clinical practice is 
urinary protein and an improvement in proteinuria at 
1  year [59] and a decrease in serum creatinine or 
proteinuria at 6  months [60], whilst it may also be 
reasonably expected that renal response may continue to 
improve beyond the ﬁ rst year of treatment and may be 
relevant to consider when identifying the maximal 
treatment diﬀ erence for a clinical trial. However, there is 
limited evidence of reliable predictors of long-term 
outcome for nonrenal SLE. For reasons discussed earlier, 
steroid-sparing eﬀ ect is an important factor when 
deciding the immuno sup pres sant of choice [56].
What disease assessment index to use?
Disease activity indices have been developed with a view 
to assess either disease activity or damage. Th e proposed 
SLE Responder Index, although used in the belimumab 
studies [61,62], has never been validated or shown to be 
reliable or sensitive to change or appropriate for wide use 
when evaluating eﬃ  cacy with other investigational agents. 
Th e key problem with global score indices is that they do 
not capture partial improvement and/or deterioration.
Th e deﬁ nitions of treatment failure and ﬂ are remain 
variable between studies, which limit direct comparison 
of eﬃ  cacy of diﬀ erent therapeutic agents. To facilitate a 
better comparison between studies, therefore, it is 
important to standardise the deﬁ nition of a ﬂ are and 
treatment failure.
Adequate follow-up period to detect signifi cant change in 
the disease activity and disease damage
Allowing an adequate follow-up period to detect 
clinically meaningful eﬀ ects is very important. For 
example, haematological abnormalities such as anaemia 
and autoimmune thrombocytopaenia and skin changes 
such as vasculitic rash improve rapidly; in contrast, 
response in nephritis may take much longer to detect. 
Other important factors such as the eﬀ ects of long-term 
accruement of organ damage and drug-related adverse 
eﬀ ects could only be detected after many years.
Defi ning the adverse eff ects
Adverse events recorded in the clinical trials in SLE have 
not been adequately standardised to allow comparison 
between trials. In chronic disease such as SLE where a 
number of treatments have proved to have modest 
eﬃ  cacy, adverse eﬀ ects associated with treatment have a 
signiﬁ cant inﬂ uence on the choice of treatment. As 
discussed, achieving primary and secondary endpoints of 
eﬃ  cacy at the expense of unacceptable adverse events 
has proven unfruitful in the case of the anti-CD20 
(ocrelizumab) in RA [39] whilst the BELONG lupus 
nephritis trial was stopped early due to an imbalance of 
infectious adverse events. Th is ﬁ nding does raise the 
question of whether the screening and monitoring 
criteria can be applied more stringently for the detection 
of risk or actual opportunistic infections prior to inclu-
sion in the study, particularly when recruiting patients 
residing in areas endemic for opportunistic infections as 
mycobacteria or hepatitis. Also, another important 
question remaining unanswered is whether the adverse 
eﬀ ects of biological agents are inﬂ uenced by other 
identiﬁ able factors such as disease history and treatment 
as well as a patient’s immunology or indeed ethnicity. A 
robust deﬁ nition of categories of adverse events therefore 
needs to be tested in clinical trials to understand and 
compare the safety of interventions in clinical trials. For 
example, is mycophenolate safe to use following rituxi-
mab induction therapy? Does the dose of mycophenolate 
need to be modiﬁ ed to a low-dose regime or should an 
alternative less potent immunosuppressant such as 
azathioprine be used? Further, the dose of drug may be 
better adjusted based on patient characteristics; for 
example, a dose deﬁ ned by the weight of the patient 
rather than a predeﬁ ned dose (that is, 2 to 3  g). Th is 
factor is especially important when considering the use 
of mycophenolate in patients with low body mass index; 
for these patients, even 2 g may be a relatively high dose, 
especially when used in the maintenance regime 
following rituximab induction therapy. Th e recording of 
adverse events in clinical trials and open studies could be 
standardised adhering to rheumatology-speciﬁ c criteria 
such as the OMERACT [63].
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Key messages
• B-cell depletion with rituximab continues to be used in 
clinical practice for the treatment of refractory SLE, on 
the basis of a considerable number of publications 
describing the safety and eﬃ  cacy data from small open 
studies and clinical experience whilst noting that it has 
not been approved by health authorities for the 
treatment of lupus.
• Contributing features that may have led to the failure 
of DBRCTs with anti-CD20-mediated B-cell depletion 
or at least identifying any true treatment eﬀ ect size 
probably include concomitant use of high-dose steroids, 
stringent and nonorgan-speciﬁ c clinical res ponse cri-
teria, too short a follow-up, and, from a statistical pers-
pective, the sample size. However, the trials conﬁ rm 
the safety of repeated treatment with rituximab.
• A better response to rituximab detected in patients of 
African-American and Hispanic ancestry highlights 
the importance of preplanned subgroup analysis and 
the need to better understand the potential disease 
drivers of a treatment eﬀ ect when compared with a 
standard-of-care regimen in a trial setting.
• Th e signiﬁ cant biological eﬀ ects seen with rituximab 
need to be monitored to assess clinical beneﬁ t and risk 
in the long term.
• Future clinical trial design in SLE and lupus nephritis 
may be guided by the key working groups of experts, 
including the European League Against Rheumatism 
task force, in order to achieve standardisation and to 
continually apply lessons from both clinical and trial 
experience.
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